| |||||||||||||||
Type Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Generation N?+2p+N1 Donating Investigator Robert Coffey, Vanderbilt University Medical Center Appearance
multiple coat colors
Related Genotype: segregating for Tyrp 1b and Myo5adDescription
Mice are viable and fertile, although mice of the most extensively studied line lactate insufficiently to support the litter. Virgin transgenic mice show no mammary gland abnormalities prepubertally, but adult virgin mice have considerable alveolar gland hyperplasia. Pregnant transgenic mice show marked proliferation of the stromal cells, and alveolar secretion is markedly increased compared to nontransgnic mice. After multiple pregnancies, isolated adenocarcinomas develop. There is no apparent phenotypic effect in males. In females, transgene expression is localized to the small ducts and alveoli in both virgin and pregnant mice as evidenced by in situ hybridization and by immunohistochemistry. Immunostaining also reveals some stromal staining in the hyperplastic areas. Egfr mRNA expression is also increased in mammary tissues expressing high levels of the transgene. Crosses between TGFA transgenic mice and TGFB1 transgenic mice demonstrate that these growth factors oppose each other's action on mammary gland development. The TGFA transgenic mice may also be useful in crosses with mice carrying mutations in the EGF and EGFR families. The putative tumor-promoter effect of TGFA may also be useful in enhancing the detection of tumor-initiating events and in determining the actions of putative metastases-inducing genes.
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
Strains carrying other alleles of TGFA
002459 B6D2-Tg(MMTVTGFA)254Rjc/J 002953 FVB.Cg-Tg(MMTVTGFA)254Rjc/J 002421 FVB/N-Tg(MtTGFA)100Lmb/J 002422 STOCK Tg(MtTGFA)42Lmb/J 003722 SW.Cg-Tg(MtTGFA)42Lmb/J View Strains carrying other alleles of TGFA (5 strains)
Strains carrying other alleles of MMTV
004997 B6.Cg-Tg(MMTV-TGFBR2)7Hlm/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 007962 B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J 002375 B6;D2-Tg(MMTVTGFB1)46Hlm/J 010576 B6;SJL-Tg(MMTV-rtTA)4-1Jek/J 002459 B6D2-Tg(MMTVTGFA)254Rjc/J 002870 B6SJL-Tg(Wnt1)1Hev/J 005038 FVB-Tg(MMTV-Erbb2)NK1Mul/J 004363 FVB.Cg-Tg(MMTV-vHaras)SH1Led/J 002953 FVB.Cg-Tg(MMTVTGFA)254Rjc/J 002934 FVB.Cg-Tg(Wnt1)1Hev/J 002437 FVB/N-Tg(MMTV-Notch4)3Rnc/J 002374 FVB/N-Tg(MMTV-PyVT)634Mul/J 002376 FVB/N-Tg(MMTVneu)202Mul/J 002933 FVB/NJ-Tg(MMTVTGFB1)46Hlm/J 003690 STOCK Tg(MMTV-Cdc37)1Stp/J 003337 STOCK Tg(MMTV-PIP)1Shu/J 003551 STOCK Tg(MMTV-cre)1Mam/J 003553 STOCK Tg(MMTV-cre)4Mam/J View Strains carrying other alleles of MMTV (19 strains)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Tg(MMTVTGFA)29Rjc/0
involves: C57BL/6 * DBA/2
- endocrine/exocrine gland phenotype
- *normal* endocrine/exocrine gland phenotype (MGI Ref ID J:28453)
- male mice exhibit normal mammary and salivary gland
- abnormal mammary gland morphology (MGI Ref ID J:28453)
- after formation of tumors at 3 months, glands are small with minimal secretion in the lumen and the stroma around the glands is abundant but mitosis and dysplasia of the epithelial or stromal cells is not observed
- stroma between the mammary glands is hyperplastic
- at 5 months two females develop bilateral swollen, lumpy thoracic mammary glands with abundant alveolar and ductal proliferation containing abundant secretions
- at 5 months of age, female mice exhibit epithelial and stromal proliferation
- the female founder mouse developed a mass during pregnancy that receded followed by development of masses in the inguinal fat pad and soft tissues of the upper thorax consisting of adenocarcinoma without metastasis
- at 4 months of age, female mice develop numerous lumps within thoracic and inguinal areas of the mammary glands with large cystic spaces and abundant secretion within the lumen along with solid hyperplasias
- female mice exhibit abnormal ductal trees
- female mice exhibit cystically dilated alveoli
- abnormal mammary gland growth during pregnancy (MGI Ref ID J:28453)
- during pregnancy, female mice exhibit increased stromal cell proliferation, more prominent nuclei of epithelial cells, and production of more secretion than in wild-type mice
- after 3 month, female mice that have been pregnant develop an inguineal mammary fat pad that develops into a circumscribed, firm tumor
- during pregnancy, female mice exhibit abnormal mammary gland hyperplasia with cysts that are more prominent and secretions that are more inspissated than in wild-type mice
- mammary gland alveolar hyperplasia (MGI Ref ID J:28453)
- at day 90
- mammary gland duct hyperplasia (MGI Ref ID J:28453)
- at 5 months of age
- mammary gland hyperplasia (MGI Ref ID J:71696)
- female mice exhibit lobular development similar to a lactating wild-type mice except that the alveoli are irregular and dilated with interstitial stroma edema and a modest increase in leukocyte infiltration
- however, nulliparous mice exhibit minimal lobular development and no stromal response
- virgin females exhibit papillary hyperplasia
- tumorigenesis
- mammary gland tumor (MGI Ref ID J:28453)
- after 3 month, female mice that have been pregnant develop an inguineal mammary fat pad that develops into a circumscribed, firm tumor
- tumors have fibrous encapsulation with no evidence of local invasion and are composed of numerous well-formed alveoli with rare mitotic figures
- adenomas develop in multiparous female mice
- at 17 months, 53% of female mice exhibit solid tumors
- in 6% of female mice at day 250
- following treatment with 0.5 mg DMBA at 56 days after birth, 50% of mice develop mammary gland tumors at day 180 and 65% at day 250 compared to only 6% of similarly treated wild-type mice at day 250
- following treatment with 0.5 mg DMBA at 56 days after birth, mice develop an average of 3.6 tumors per mouse with 60% of tumors arising in the thoracic mammary gland and 31% in the inguinal mammary gland
- following treatment with 0.5 mg DMBA at 21 days after birth, 50% of mice develop mammary tumors within 250 days at a frequency of 2.4 tumors per mouse compared to no tumor development in similarly treated wild-type mice
- tumor onset is delayed when mice are treated treatment with 0.5 mg DMBA at 21 days after birth compared to at 56 days after birth
- mammary adenocarcinoma (MGI Ref ID J:28453)
- the female founder mouse developed a mass during pregnancy that receded followed by development of masses in the inguinal fat pad and soft tissues of the upper thorax consisting of adenocarcinoma without metastasis
- solid hyperplasias develop into adenocarcinomas
- in 40% of female mice
- following treatment with 0.5 mg DMBA at 21 or 56 days after birth, predominantly mammary adenocarcinomas form with occasional squamous differentiation
- squamous cell carcinoma (MGI Ref ID J:72080)
- following treatment with 0.5 mg DMBA at 21 or 56 days after birth, predominantly mammary adenocarcinomas form with occasional squamous differentiation
- behavior/neurological phenotype
- abnormal nursing (MGI Ref ID J:28453)
- females cannot suckle her young
- females cannot nurse her young
- reproductive system phenotype
- abnormal mammary gland morphology (MGI Ref ID J:28453)
- after formation of tumors at 3 months, glands are small with minimal secretion in the lumen and the stroma around the glands is abundant but mitosis and dysplasia of the epithelial or stromal cells is not observed
- stroma between the mammary glands is hyperplastic
- at 5 months two females develop bilateral swollen, lumpy thoracic mammary glands with abundant alveolar and ductal proliferation containing abundant secretions
- at 5 months of age, female mice exhibit epithelial and stromal proliferation
- the female founder mouse developed a mass during pregnancy that receded followed by development of masses in the inguinal fat pad and soft tissues of the upper thorax consisting of adenocarcinoma without metastasis
- at 4 months of age, female mice develop numerous lumps within thoracic and inguinal areas of the mammary glands with large cystic spaces and abundant secretion within the lumen along with solid hyperplasias
- female mice exhibit abnormal ductal trees
- female mice exhibit cystically dilated alveoli
- abnormal mammary gland growth during pregnancy (MGI Ref ID J:28453)
- during pregnancy, female mice exhibit increased stromal cell proliferation, more prominent nuclei of epithelial cells, and production of more secretion than in wild-type mice
- after 3 month, female mice that have been pregnant develop an inguineal mammary fat pad that develops into a circumscribed, firm tumor
- during pregnancy, female mice exhibit abnormal mammary gland hyperplasia with cysts that are more prominent and secretions that are more inspissated than in wild-type mice
- mammary gland alveolar hyperplasia (MGI Ref ID J:28453)
- at day 90
- mammary gland duct hyperplasia (MGI Ref ID J:28453)
- at 5 months of age
- mammary gland hyperplasia (MGI Ref ID J:71696)
- female mice exhibit lobular development similar to a lactating wild-type mice except that the alveoli are irregular and dilated with interstitial stroma edema and a modest increase in leukocyte infiltration
- however, nulliparous mice exhibit minimal lobular development and no stromal response
- virgin females exhibit papillary hyperplasia
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Cancer Research
Increased Tumor Incidence
Mammary Gland Tumors
| Allele Symbol | Tg(MMTVTGFA)29Rjc | ||
|---|---|---|---|
| Allele Name | transgene insertion 29, Robert J Coffey | ||
| Allele Type | Transgenic (random, expressed) | ||
| Mutation Made By | Robert Coffey, Vanderbilt University Medical Center | ||
| Strain of Origin | (C57BL/6 x DBA/2)F2 | ||
| Expressed Gene | TGFA, transforming growth factor, alpha, human | ||
| Promoter | MMTV, Mouse Mammary Tumor Virus, MMTV | ||
| Molecular Note | This transgene contains the mouse mammary tumor virus LTR and the normal allele of the human transforming growth factor alpha gene. The vector also contains exons 2 and 3 of the rabbit beta-globin gene. Lines 254, 257, 64 and 29 were produced. [MGI Ref ID J:28453] | ||
Genotyping Protocols
Tg(MMTVTGFA), Standard PCR
Tg(MMTVTGFA), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Matsui Y; Halter SA; Holt JT; Hogan BL; Coffey RJ. 1990. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61(6):1147-55. [PubMed: 2161707] [MGI Ref ID J:28453]
Halter SA; Dempsey P; Matsui Y; Stokes MK; Graves-Deal R; Hogan BL; Coffey RJ. 1992. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol 140(5):1131-46. [PubMed: 1316084] [MGI Ref ID J:72085]
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16(10):5726-36. [PubMed: 8816486] [MGI Ref ID J:35344]
Pierce DF Jr; Gorska AE; Chytil A; Meise KS; Page DL; Coffey RJ Jr; Moses HL. 1995. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A 92(10):4254-8. [PubMed: 7753792] [MGI Ref ID J:71696]
Tg(MMTVTGFA)29Rjc relatedCardiff RD; Anver MR; Gusterson BA; Hennighausen L; Jensen RA; Merino MJ; Rehm S; Russo J; Tavassoli FA; Wakefield LM; Ward JM; Green JE. 2000. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [see comments] Oncogene 19(8):968-88. [PubMed: 10713680] [MGI Ref ID J:61035]
Cardiff RD; Munn RJ. 1995. Comparative pathology of mammary tumorigenesis in transgenic mice. Cancer Lett 90(1):13-9. [PubMed: 7720037] [MGI Ref ID J:72081]
Coffey RJ Jr; Meise KS; Matsui Y; Hogan BL; Dempsey PJ; Halter SA. 1994. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene. Cancer Res 54(7):1678-83. [PubMed: 8137281] [MGI Ref ID J:72080]
Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL. 2003. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 163(4):1539-49. [PubMed: 14507660] [MGI Ref ID J:85799]
Halter SA; Dempsey P; Matsui Y; Stokes MK; Graves-Deal R; Hogan BL; Coffey RJ. 1992. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol 140(5):1131-46. [PubMed: 1316084] [MGI Ref ID J:72085]
Jatoi A; Cleary MP; Tee CM; Nguyen PL. 2001. Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing mice. Ann Nutr Metab 45(3):116-20. [PubMed: 11423703] [MGI Ref ID J:70639]
Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL. 2000. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A 97(17):9609-14. [PubMed: 10931950] [MGI Ref ID J:64071]
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16(10):5726-36. [PubMed: 8816486] [MGI Ref ID J:35344]
Norgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ Jr; Poulsen HS; Moses HL. 1999. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5(1):35-42. [PubMed: 9918200] [MGI Ref ID J:52053]
Pierce DF Jr; Gorska AE; Chytil A; Meise KS; Page DL; Coffey RJ Jr; Moses HL. 1995. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A 92(10):4254-8. [PubMed: 7753792] [MGI Ref ID J:71696]
Witty JP; Lempka T; Coffey RJ Jr; Matrisian LM. 1995. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 55(7):1401-6. [PubMed: 7882342] [MGI Ref ID J:56328]
Xie L; Xu BJ; Gorska AE; Shyr Y; Schwartz SA; Cheng N; Levy S; Bierie B; Caprioli RM; Moses HL. 2005. Genomic and proteomic analysis of mammary tumors arising in transgenic mice. J Proteome Res 4(6):2088-98. [PubMed: 16335954] [MGI Ref ID J:106939]
Colony Maintenance
Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $1900.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Pricing for International shipping destinations |
|
Animals Provided
Price (US dollars $) Cryorecovery Fee $2470.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
| Standard Supply | Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| Noncarrier | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.